



JAMMU AND KASHMIR MEDICAL SUPPLIES CORPORATION LTD.

(Public Sector Undertaking of Govt. of Jammu & Kashmir)

Corporate Head Office: Temp. Address Plot No. 5B, Friends Colony Satyam Road Trikuta Nagar, Jammu

Corporate Office: Opposite State Motor Garage, near Haj House Bemina Srinagar

Telephone: 0191-2580842, Fax: 0191-2581845 (Jammu); Telefax: 0194-2432008 (Srinagar)

Minutes of introductory meeting held at Corporate Office, Jammu with the MD, JKMSCL and prospective manufacturers/Bidders on 25-07-2022.

===

An introductory meeting with MD, JKMSCL and firms and prospective bidders was held on 25-07-2022 at 3:00 PM in the office chamber of the Managing Director, J&K Medical Supplies Corporation Ltd. Those who were not able to attend the meeting in person were available via video conferencing. The following Officer/Officials of JKMSCL attended the meeting.

S.No	Name of the Officer/Official	Designation
1.	Dr. Abdul Majid Mirab	General Manager (P&S/Drugs)
2.	Mr. Mohd. Arshad Chowdhary	Financial Advisor/CAO
3.	Ms. Saba Noor,JKAS	Dy. General Manager(Adm.)
4.	Dr. Vinay Chib	Dy. General Manager (P&S/IT)
5.	Nazir Ahmed Wani	I/c QC Cell
6.	Dr. Ujala Verma	Medical Officer (QC)
7.	Dr. Usha Attri	Medical Officer (SWH)
8.	Dr. Prince Aneet Singh	Medical Officer (Evaluation)
9.	Dr. Qazi Qammer	Medical Officer (Tendering)
10.	Mr. Pawan Kumar	Accounts Officer
11.	Mr. Basant Sharma	Section Officer
12.	Mr. Sanjay Pandoh	Asstt Accounts Officer

Besides above, the representatives of below mentioned firms also participated in the meeting:

S.No	Name of the Representative	Name of the firm
1.	Mr. Vinod Ganjoo	M/s.Life Line Enterprises
2.	Mr. Vijay Tickoo	M/s.Siddidatta Associates
3.	Mr. Sandeep Slathia	M/s.Jackson Lab P.Ltd
4.	Mr. Vivek Sareen	M/s.Access Traders
5.	Mr. Vijay Bhardwaj	M/s.Bhardwaj Agencies,Jammu
6.	Mr. Sandeep Gupta	M/s.BDS Inc
7.	Mr. Raj Kumar	M/s. B.R.Medical
8.	Mr. Ajay Raina	M/s. Coulson & co

15.	Mr. Irfan Shamus	M/s. L.M.Agencies
16.	Mr. Ashish Hasija	M/s. Meril Life Sciences
17.	Mr. Imran Sultan	M/s. Novolife Healthcare P.Ltd.
18.	Mr. Hameet Singh	M/s. Cipla Ltd
19.	Mr. Anoop Raina	M/s. Bhawani Enterprises
20.	Mr. Manzoor Chisti	M/s.Hussain Brothers
21.	Mr. Ashok Amla	M/s. Confident Dental
22.	Mr. Anil Bhan	M/s.Vikrant Life Sciences
23.	Mr. Niklesh Tickoo	M/s. Medilux Systems
24.	Mr. Ganesh Kumar	M/s. Health Imaging
25.	Mr. Rajan Gupta	M/s. S.S.Agencies.
26.	Dr. Vijay Koul	M/s. Vikrant Life Sciences
27.	Mr. Bilal Ahmed	M/s.Unicure

At the outset of the meeting, Managing Director, JKMSCL welcomed all the participants followed by a brief introduction. Thereafter, different issues were deliberated upon which are hereunder:

S.No	Issues discussed	Clarification & Decision
1.	<u>Timely finalization of NITs-</u> The representatives emphasized that NITs should be finalized in a time-bound manner in order to streamline the whole procurement process. It was also requested to expedite verification/re-verification process during Technical Evaluation.	It was discussed that many of the bidders do not submit proper technical bids due to which the lengthy exercise of examining and seeking minor infirmities has to be conducted. Also, repeated requests of the bidders to extend the critical dates of the NITs and delayed comments of the experts from the intending departments also hampers the tendering process. Accordingly, it was requested to all the bidders to ensure that the technical bids uploaded are complete in all respects so that the crucial time is saved. Also, it was apprised by the Chair that HODs of different departments have been requested to nominate a Nodal Officer at their end who shall liaison with JKMSCL to ensure seamless communication. The evaluation teams were also asked to expedite Technical Evaluation process without compromising on quality.
2.	<u>Mentioning of the quantity in the NITs floated by JKMSCL:</u> The firms requested that tentative quantities should be mentioned in the NITs especially of drugs & disposables.	The Chair directed the concerned that henceforth all the NITs floated by JKMSCL for drugs and disposables shall have the indicative quantity that will be mean of last 2-3 years, so that the prospective bidders shall have the idea of the same. However, this would be only for indicative purpose and the final requirement shall be as per the requisition of the end users. (Action to be taken by-GM-Drugs)
3.	<u>Time frame for verification boards-</u> Bidders raised the issue of a proper time frame with respect to conducting verification boards at different Drug Warehouses.	The Chair directed all the Medical Officers of respective drug warehouses to conduct weekly verification boards to address the issue. (Action to be taken by-MOs of DWHs)
4.	Pending quality check of some drugs for which RC is not available with empanelled labs.	It was decided that matter will be taken up in the ensuing Purchase Committee Meeting which is scheduled to be held by the start of next week. Further, I/c QC section & all drug warehouses were asked to expedite the process regarding QC & sending samples respectively at their ends in general.



5.	<p><u>Issue of pending installations of Machinery & Equipment's at different health institutions-</u></p> <p>Firms represented the issue of pending installations despite their successful execution of supplies, due to which payments cannot be made to them.</p>	<p>It was discussed that the issue shall be taken up with the HODs on priority since the supplies are made as per their respective requisitions.</p>
6.	<p>EMD as well as turnover exemption.</p>	<p>As per rule 170 of GFR, MSMEs, start-ups are exempted from submission of bid security(EMD). Accordingly, all such firms who are willing to participate in the tenders floated by JKMSCL are being given the said exemption subject to the production of the requisite documentary proof.</p> <p>As far as relaxation in turnover criteria is concerned, the same is under review as per OM No F.20/2/2014-PPD issued by the Ministry of Finance, and the decision shall be communicated accordingly.</p>
7.	<p>Relaxation in client base (past experience) from last 3 years to 3 years in the last 5 years.</p>	<p>It was discussed that the matter shall be studied and a pragmatic decision shall be taken by taking into consideration the Covid-19 scenario, wherein attention was focused in containing the pandemic due to which various other procurements were stalled.</p>
8.	<p>Request for issuing Rate Contract for 1 year instead of 2 years.</p>	<p>It was discussed that the finalization of tenders takes considerable amount of time wherein various extensions in critical dates are to be issued on the requests of firms & experts. As such, issuing Rate Contracts for 1 year only will not be advisable vis a vis meeting the urgent requirements of the end users. However, the matter shall be reviewed by taking the holistic view of the issue.</p>
9.	<p>Waiving of tender charges & tender procurement fee for the cancelled tenders.</p>	<p>Since the tenders are to be processed by following due procedures in order to arrive at the final decision vis a vis the said tender, tender charges or tender processing fee cannot be waived even if tender is cancelled as such.</p>
10.	<p>Issue of sending bills to the Accounts Section in a timely manner to resolve the pendency in payments.</p>	<p>The Chair directed the concerned Drug Ware Houses to send bills as soon as they are completed in all respects to the Accounts Section without any delay so that the payments are made in a timely manner. (Action to be taken by respective Medical Officers of Drug Warehouses)</p>
11.	<p>Issue of Loan License-The firms requested JKMSCL to consider the manufacturers that are operating on loan licenses.</p>	<p>It was decided that JKMSCL shall review and take an informed decision on the same.</p>
12.	<p>Reasons for cancellation of NITs- The representatives requested that the reasons for cancellation of tenders be communicated to them.</p>	<p>The chair directed that henceforth the reason for cancellation of an NIT shall be reflected in the cancellation notice without fail. (Action to be taken by GM (Adm) & GM (P&S))</p>
13.	<p>Representation for making Amendments as per GFR-2017</p>	<p>It was decided that necessary amendments shall be considered after thoroughly studying Standard Procurement Procedure of JKMSCL & GFR-2017.</p>
14.	<p>Replies to the representations/clarifications sought in official e-mails-Issuing firms represented that many a times the replies/clarifications are not received by them with respect to the e-mails sent on official mail IDs of JKMSCL.</p>	<p>The Chair directed all the concerned to ensure that the replies to such e-mails are made without delay so that any sort of miscommunication is prevented between JKMSCL & the firms (Action to be taken by all the concerned)</p>


4

15.	Receipt of samples at Corporate Office Srinagar for sample based items.	It was decided that small samples like those of Disposable, Dressings can be submitted at Corporate Office Srinagar well in time which shall be sent to the Sample Warehouse of JKMSCL at Jammu.
16.	Exemption of artwork in case of meagre quantity drugs.	It was clarified that as per approval accorded by Board of Directors of JKMSCL in its 5 th Meeting and subsequent authorization issued vide order no 36 JKMSCL of 2019 dated 25.06.2019, meagre quantity drugs with tamper proof sticker where the demand is less than 50% of the batch size or below 10000 (whichever is less) are accepted.

In the end, the bidders were requested to submit a compiled representation to JKMSCL. Clarifications/Decisions shall be made at the section and policy level accordingly.

The Meeting ended with the vote of thanks to the Chair.

Sd/-

Managing Director
J&K Medical Supplies Corporation Ltd.

NO. JKMSCL/DGM (ADM) MOM/6774-79
Copy to:-

Date: 28-07-2022

1. FA/CAO, JKMSCL.
2. GM (P&S), JKMSCL.
3. GM (ADM.), JKMSCL
4. All Medical Officers of Drug Ware Houses of JKMSCL for compliance.
5. P.S to Principal Secretary to Govt., H&ME.
6. Assistant programmer I/c website to upload the circular on JKMSCL website.
7. All concerned sections for compliance.


Deputy General Manager
J&K Medical Supplies Corporation Ltd.

